Hematologic malignancies following immune checkpoint inhibition for solid tumors.
Mick J M van EijsLotte E van der WagenRogier MousRoos J LeguitLisette van de CorputAnne S R van LindertBritt B M SuelmannAnna M KamphuisStefan NierkensKarlijn P M SuijkerbuijkPublished in: Cancer immunology, immunotherapy : CII (2022)
Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.
Keyphrases
- acute myeloid leukemia
- chronic myeloid leukemia
- bone marrow
- end stage renal disease
- dendritic cells
- chronic kidney disease
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- primary care
- prognostic factors
- peritoneal dialysis
- copy number
- genome wide
- gene expression
- dna methylation
- immune response
- single molecule
- combination therapy
- genome wide identification
- bioinformatics analysis